Perceptive Advisors
Perceptive Advisors is an investment firm focused on supporting innovations in the life sciences. Founded in 1999, the firm manages capital across multiple strategies (Life Sciences, Credit Opportunities, Discovery, Venture Capital) to provide equity and debt financing, structured financings, and operational support to companies across the healthcare value chain.
Perceptive Advisors
Services
Venture capital investments (seed / Series A / select growth)
Actively manages venture funds that provide lead or co-lead Series A investments and select growth-stage financings. Typical commitments in Series A are $10–40 million; the team also participates as syndicate investors in larger early-stage rounds.
Private credit financing (Credit Opportunities)
Provides customized debt financing solutions to healthcare companies across stages and subsectors, focusing on minimally dilutive capital and flexible structures as alternatives to equity or crossover financings.
Discovery / structured financings and company building
Discovery Fund provides structured solutions (preferred equity and/or convertible debt), asset carve-outs, and roll-up opportunities aimed at later-stage development and commercial-stage companies requiring substantial capital to reach operational inflection points.
Life sciences public and private investing
Investment strategy that invests across a company’s lifecycle in public and private companies developing drugs, devices, and diagnostics, including participation in early and late stage venture, crossover rounds, IPOs and public follow-on financings.
Active board-level and operational support
Provides active partnership with management teams through Board seats and strategic advice, bringing operational and regulatory experience to support company growth and governance.
Investment across the capital structure
Invests across private equity, private credit, structured financings and public equities to provide appropriate financing solutions aligned with company objectives.
Venture capital investments (seed / Series A / select growth)
Actively manages venture funds that provide lead or co-lead Series A investments and select growth-stage financings. Typical commitments in Series A are $10–40 million; the team also participates as syndicate investors in larger early-stage rounds.
Private credit financing (Credit Opportunities)
Provides customized debt financing solutions to healthcare companies across stages and subsectors, focusing on minimally dilutive capital and flexible structures as alternatives to equity or crossover financings.
Discovery / structured financings and company building
Discovery Fund provides structured solutions (preferred equity and/or convertible debt), asset carve-outs, and roll-up opportunities aimed at later-stage development and commercial-stage companies requiring substantial capital to reach operational inflection points.
Life sciences public and private investing
Investment strategy that invests across a company’s lifecycle in public and private companies developing drugs, devices, and diagnostics, including participation in early and late stage venture, crossover rounds, IPOs and public follow-on financings.
Active board-level and operational support
Provides active partnership with management teams through Board seats and strategic advice, bringing operational and regulatory experience to support company growth and governance.
Investment across the capital structure
Invests across private equity, private credit, structured financings and public equities to provide appropriate financing solutions aligned with company objectives.
Portfolio
Series A lead, March 2020 (listed as a selected recent venture capital investment).
#Biotechnology
Series A lead, June 2020 (listed as a selected recent venture capital investment).
#Medtech / Vascular therapies
Series B syndicate investor, December 2022 (venture capital page).
#Biotechnology / Therapeutics
Listed among investments; described as developing optimized AAV vectors.
#Gene therapy / Biopharmaceuticals
Series A lead, March 2020 (listed as a selected recent venture capital investment).
#Biotechnology
Series A lead, June 2020 (listed as a selected recent venture capital investment).
#Medtech / Vascular therapies
Series B syndicate investor, December 2022 (venture capital page).
#Biotechnology / Therapeutics
Listed among investments; described as developing optimized AAV vectors.
#Gene therapy / Biopharmaceuticals